What happens after import before QP certification in Ireland is a critical part of the regulatory pathway for non-EU Marketing Authorisation Holders and clinical trial sponsors. The physical arrival of a medicinal product is not the end of the supply chain; it is the beginning of a tightly controlled regulatory sequence that must be completed before a Qualified Person (QP) can certify the batch for release to the European market.
A frequent misconception is that once goods clear customs and are received at an authorised facility, they are ready for distribution. EU pharmaceutical legislation requires a clear separation between physical importation under a Manufacturer’s/Importer’s Authorisation (MIA) and formal batch certification under EU GMP Annex 16. Only after the applicable certification and release requirements have been completed can the batch be released for sale or supply to the market. For a broader overview of the full pathway, see our guide on what is EU batch release.
This article explains the practical sequence that takes place after a medicinal product arrives in Ireland, the regulatory requirements that apply at each stage, the issues that most often extend the quarantine period, and the steps companies can take to keep the process moving efficiently.
What Happens After a Medicinal Product Arrives in Ireland?
- The shipment is received at the authorised import site.
- The batch remains under controlled/quarantine status.
- Documentation, transport conditions and applicable testing are reviewed.
- Deviations and discrepancies are assessed.
- The QP reviews the evidence required for certification.
- The QP certifies the batch under EU GMP Annex 16.
- The batch can then be released for sale or supply where the applicable requirements are satisfied.
Physical Arrival and Quarantine Status Control
When a medicinal product is imported into Ireland from a third country, it must enter through a site that holds the appropriate Manufacturer’s/Importer’s Authorisation issued by the Health Products Regulatory Authority (HPRA). Upon receipt, the batch is placed under controlled quarantine status. This is a fundamental control within EU Good Manufacturing Practice.
Quarantine status has both physical and system dimensions:
- The batch is physically segregated from released stock.
- The quarantine status is recorded in the warehouse management system or quality management system.
- The product cannot be released for sale or supply until the applicable release requirements, including QP certification where required, have been completed.
Quarantine does not necessarily mean that no further authorised activity can take place. Where permitted by the applicable authorisation and procedures, imported bulk or intermediate products may undergo further controlled processing while their regulatory status remains appropriately managed.
This controlled status remains in force until the applicable certification and release requirements have been completed. The principles governing this stage are set out in EU GMP Annex 21, which describes the responsibilities of the MIA holder for the importation and handling of medicinal products from outside the EU/EEA. More detail on the MIA framework itself is available on our EU pharmaceutical importation & MIA licence page.
During the receipt phase, the import site verifies the physical integrity of the shipment. This includes review of transport documentation, temperature monitoring records and any evidence of excursions. Where temperature or other storage conditions have been breached, the excursion must be documented and assessed for impact on product quality before the batch can progress. Failure to address transport deviations at this stage can contribute to later delay.
Technical and Import Compliance Preparation
Once the product is under quarantine, a structured technical and compliance review begins. This review prepares the batch documentation for formal assessment by the Qualified Person and forms an essential part of meeting the requirements of EU GMP Annex 16.
Typical elements of this preparation include:
- Confirmation that the manufacturing, testing and packaging sites involved have appropriate GMP status and that their activities align with the Marketing Authorisation or Clinical Trial Authorisation.
- Review of the complete Batch Manufacturing Record and packaging documentation.
- Assessment of analytical results against the registered product specifications.
- Evaluation of any deviations, out-of-specification results or process changes, including the associated investigations and CAPAs.
- Confirmation that transport and storage conditions remained within the required limits throughout the supply chain.
- Verification of the existence and current status of relevant Technical Agreements.
The QP must have appropriate assurance regarding the sites used, their GMP compliance, and their alignment with the approved dossier. While EudraGMDP is an important source of information on manufacturing and import authorisations, the regulatory requirement is that the QP has sufficient evidence of site qualification and compliance rather than a single universal database check for every site. Annex 21 also provides for qualification and periodic audit of third-country manufacturers as part of the Pharmaceutical Quality System.
Where EU re-testing is required after importation, the results of that testing must also be available and reviewed before certification can proceed. Whether re-testing is required depends on the applicable legal framework, the country of origin and the status of any applicable Mutual Recognition Agreement or other relevant arrangement. Related guidance on importer obligations can be found in our article on EU GMP requirements for importers.
A formal Technical Agreement between the MIA holder and the third-country manufacturer is an important supporting document. It defines responsibilities for documentation provision, deviation handling, change notification and communication timelines. Clear agreements reduce the risk of incomplete files arriving at the import site.
QP Certification and Release from Quarantine
The Qualified Person’s certification under EU GMP Annex 16 is a separate legal act from the physical importation process. Before certification can be completed, the QP must have access to the information and evidence necessary to support the certification decision.
In practical terms, the QP needs sufficient assurance that the batch corresponds to the authorised product and that the relevant manufacturing, testing, importation, storage and quality activities have been performed in accordance with the applicable requirements. This includes consideration of relevant deviations, investigations and test results.
When the technical preparation is finished and the required evidence is available, the QP independently assesses the batch against the requirements of EU GMP and the relevant Marketing Authorisation or Clinical Trial Authorisation. The QP’s certification decision is personal and carries legal responsibility under EU pharmaceutical legislation. Overall responsibility for placing authorised products on the market remains with the Marketing Authorisation Holder.
If the QP is satisfied, the batch is certified. Only then, once the applicable release requirements have also been met, can the batch move from quarantine to released status and become available for sale or supply as appropriate.
For a deeper explanation of the certification process itself, see our guide to QP certification and batch release. Further detail on the certification standard is available on the EU GMP Annex 16 certification service page.
Issues That Can Extend the Quarantine Period
Common issues that can extend the quarantine period include:
- Incomplete or poorly organised batch documentation arriving from the third-country manufacturing site.
- Significant open deviations or investigations for which the required assessment and supporting documentation are not yet available.
- Missing or inadequate temperature monitoring data for the transport stage.
- Uncertainty about whether EU re-testing is required and the associated timelines.
- Mismatch between the manufacturing or testing sites used and those listed in the Marketing Authorisation or applicable trial documentation.
- An outdated product specification or dossier version, particularly where this affects an investigational medicinal product.
Most of these issues can be reduced through better preparation and clearer communication before the product leaves the third-country site. Many of the same root causes appear in our wider discussion of compliance mistakes in EU pharma importation.
Special Considerations for Investigational Medicinal Products
For investigational medicinal products (IMPs), additional requirements apply under the EU Clinical Trials Regulation and applicable GMP requirements. The importation and certification arrangements should therefore be confirmed against the specific clinical trial, product status and applicable IMP MIA scope.
For clinical trial sponsors, this makes early alignment between the sponsor, manufacturer, importer and QP particularly important. Documentation and testing expectations should be established before shipment rather than being resolved only after the product reaches Ireland.
Practical Recommendations for a Smoother Process
Companies that achieve more predictable timelines between arrival and certification can benefit from a small number of disciplined practices:
- Assemble the complete batch documentation package, including manufacturing records, certificates of analysis, transport data and relevant investigations, before the product is despatched.
- Where possible, resolve significant deviations and investigations before shipment. Where issues remain open, ensure that the required documentation, risk assessment and escalation process are already in place so the QP can assess their impact without avoidable delay.
- Confirm the GMP status and authorisation coverage of all relevant manufacturing and testing sites before the batch is produced.
- Clarify testing requirements, including any need for EU re-testing, well in advance of importation.
- Maintain clear, up-to-date Technical Agreements that define documentation expectations, communication timelines and responsibilities for deviation handling.
- Treat the period between arrival and certification as a controlled quality process rather than a simple logistics hand-over.
When these steps are taken, the QP is better able to focus on technical assessment rather than resolving missing information, helping to reduce avoidable time in quarantine.
Conclusion
Physical arrival of a medicinal product in Ireland under a Manufacturer’s/Importer’s Authorisation is a necessary step, but it is not the final regulatory step. Between arrival and QP certification lies a structured sequence of controlled status management, technical preparation, any required testing, and formal certification under EU GMP Annex 16.
Understanding this window — and preparing for it thoroughly — can help non-EU Marketing Authorisation Holders and clinical trial sponsors reduce avoidable delays and achieve a more predictable pathway to EU market access.
For support with the full pathway, see our EU pharmaceutical importation & MIA licence and Qualified Person (QP) batch release services pages.